Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RUA Life SciencesFRA:AOHA +5.22%48 PS Ratio is 4.75 as of Jul. 26, 2026, which is 3% below its 10-year median of 4.90. GuruFocus rates FRA:AOHA with a GF Score™ of 48/100 and a GF Value™ of €0.14 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 804 Medical Devices & Instruments companies, RUA Life Sciences ranks worse than 72.89% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, RUA Life Sciences's share price is €0.242.
RUA Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.05. Hence, RUA Life Sciences's PS Ratio for today is 4.75.
Warning Sign:
RUA Life Sciences PLC stock PS Ratio (=3.69) is close to 3-year high of 3.69.
The historical rank and industry rank for RUA Life Sciences's PS Ratio or its related term are showing as below:
FRA:AOHA'
s PS Ratio Range Over the Past 10 Years
Min: 0.92 Med: 4.9 Max: 51.97
Current: 5.45
During the past 13 years, RUA Life Sciences's highest PS Ratio was 51.97. The lowest was 0.92. And the median was 4.90.
FRA:AOHA's PS Ratio is ranked worse than 72.89% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.86
vs FRA:AOHA: 5.45
RUA Life Sciences PLC revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of RUA Life Sciences was 53.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -8.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 18.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -1.30% per year.
During the past 13 years, RUA Life Sciences's highest 3-Year average Revenue per Share Growth Rate was 109.10% per year. The lowest was -69.30% per year. And the median was -1.30% per year.
Back to Basics: PS Ratio
RUA Life Sciences (FRA:AOHA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
RUA Life Sciences PS Ratio Related Terms
RUA Life Sciences PS Ratio Historical Data
* Premium members only.
The historical data trend for RUA Life Sciences's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, RUA Life Sciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RUA Life Sciences PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's PS Ratio distribution charts can be found below:
* The bar in red indicates where RUA Life Sciences's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
RUA Life Sciences's Share Price of today is €0.242.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. RUA Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.05.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
RUA Life Sciences (FRA:AOHA) has a PS Ratio of 4.75 as of Jul. 26, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on RUA Life Sciences and its competitors. This is near median its historical median of 4.90. Over the past decade, RUA Life Sciences' PS Ratio has ranged from 0.92 to 51.97. According to the industry distribution chart, RUA Life Sciences ranks #586 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 72.9%.
Is RUA Life Sciences' PS Ratio too high?
RUA Life Sciences' current PS Ratio of 4.75 is near median its 10-year median of 4.90. Over the past 10 years, this metric has ranged from a low of 0.92 to a high of 51.97. The Medical Devices & Instruments industry median PS Ratio is 2.86. RUA Life Sciences' value of 4.75 is 66.1% above this industry median. Based on the distribution chart, RUA Life Sciences ranks #586 out of 804 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, RUA Life Sciences has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RUA Life Sciences' PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, RUA Life Sciences ranks #586 out of 804 companies for PS Ratio. This places RUA Life Sciences in the lower half of its industry. The industry median PS Ratio is 2.86. RUA Life Sciences' value of 4.75 is 66.1% above this benchmark. Historically, RUA Life Sciences' own PS Ratio has ranged from 0.92 to 51.97 over the past decade. While the company's 10-year median is 4.90 vs. the industry median of 2.86, RUA Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.86, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RUA Life Sciences's current PS Ratio of 4.75 is 66.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on RUA Life Sciences and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RUA Life Sciences's current PS Ratio is 4.75, which is near median its own 10-year median of 4.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RUA Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RUA Life Sciences (FRA:AOHA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.14, compared to a current price of €0.24 — trading 72.9% above its estimated fair value. The current PS Ratio is 4.75, which is near median its 10-year median of 4.90 and 66.1% above the Medical Devices & Instruments industry median of 2.86. RUA Life Sciences' overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For RUA Life Sciences (FRA:AOHA), the current PS Ratio is 4.75 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RUA Life Sciences (FRA:AOHA) Overvalued in 2026?
Based on GuruFocus' analysis, RUA Life Sciences stock appears to be overvalued.
The current stock price of €0.24 is trading 72.9% above its estimated GF Value™ of €0.14.
GuruFocus considers RUA Life Sciences to be Significantly Overvalued.
Key valuation signals for FRA:AOHA:
PS Ratio: 4.75 (near median its 10-year median of 4.90)
GF Value™: €0.14 vs. price of €0.24 (72.9% above fair value)
Industry Position: 66.1% above the Medical Devices & Instruments median (#586 of 804)
No single metric tells the full story. See the FRA:AOHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
48GF Score
Get the complete analysis for FRA:AOHA
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AOHA has been successfully added to your 
